you, thank Yeah, Rafael.
excellent progress autoimmune, our infectious We areas. and therapeutic neuroscience across have made disease
for June, Starting second received approval adult significant gravis receptor of gMG generalized quarter. acetyl VYVGART NMPA choline several intravenous in for with antibody patients VYVGART the In are injection myasthenia who or efgatigamot treatment we or the achievements had in we positive.
treated severe as muscle by characterized inhibitors Acetylcholinesterase used China, weakness. chronic esterase steroids with and and function a are a disease, therapies. In IVIG, muscle debilitating acetyl initial patients steroids is and often inhibitors GMG choline of with immunosuppressants loss
prevalence treatment available in that options, effective show has also of with a current option and a safe high need current treatment diseases, these control patients The the faster. and efficacy symptoms can gMG with significant coupled limited are unsatisfactory treatments urgent for side-effects of
license this convenience. for increased VYVGART NMPA’s Once dosing acceptance provide flexibility for BLA applications gMG. formulation of would the we and announced of July, in approved, Furthermore, biologic or the patients subcutaneous the with
or partner happy ADHERE a top-line July, our patients in chronic results in positive argenx and In study, CIDP to demyelinating the we trial with polyneuropathy. announce inflammatory were
CIDP background key Before I in would the on to like China. presenting provide results, information
is chronic patients. characterized often function are prevalence disease debilitating and in unable impaired by estimated at to the is simple immobility, sensory is CIDP patients daily progressive weakness disease a left autoimmune time. of and often approximately balance China, The XX,XXX worsens that that with The tasks. In over walking disease difficulty perform is causing
Exchange of administration, There well immunoglobulin PLEX are as PLEX burden intravenous options of refractory the as well-known reserved limitations associated Current and plasma or and patients. with treatment are a steroids generally including for these IVIG significant therapies, to especially for IVIG, each primarily shortage IVIG.
With patients chronic in CIDP with use, effective, China. events treatment, significant need most require there well-tolerated a that become options for for alternative concern, adverse remains patients unmet are steroid treatment a convenient as as long-term and
was six representative the patients The the of entering on XXX and at or conducted X. patients largest treatment-naïve treatment enrolled those real study who population world with of included ever within months. and have ADHERE off the months was last CIDP patient patience steroids been Stage six The CIDP for IVIG least trial
In to of with time adjusted The value with that four risk of in by VYVGART doses a highly significant, stage Hytrulo. reduces VYVGART. This of X, we efficacy demonstrated a primary received primary lower made significantly P improvements endpoint. its that deterioration saw of of VYVGART the evidence was ratio by and series was a clinical we endpoints, risk hazard X.XX patients in-cap up our as a B, that indicating of to XX%. full relapse XX% well-designed, driven trial of placebo-control relapse Stage patients Hytrulo demonstrating XX% first
strong and provides symptoms Hytrulo evidence CIDP data patients. in positive that This disease improves clinical meaningfully stabilizes VYVGART
dramatically studies, VYVGART treatment Therefore, treatments. with efgartigimod favorable treatment this WE Hytrulo clear has there's the safety profile. paradigm had to for over change benefit believe the a other CIDP a China. in in potential existing As profile,
significant also across multiple potential see We a of indications. efgartigimod
of to We a with ADHERE similar contributed work study the rgenx partner indication number where on patients. will continue to Zai expansion our significant
caused pneumonia our infectious Innoviva partner ventilator-associated DURAL, adults Acinetobacter Sulbactam-Durlobactam May, pneumonia Entasis, strains for in portfolio, with drug now FDA our announced baumannii. susceptible by bacterial disease and the in hospital-acquired or the of approved of that Regarding treatment
priority no this February. to in can It bringing adequately or novel accepted to review. Our now because CRAB of NMPA infections Pacific versus forward carbapenem-resistant of drug under often resistance. and by NDA treated is Asia the China We be longer was China multi-drug frequent look in and
for June bridging China our combination China xanomeline to of Switching now in in Karuna are clinical acute a support which initiated we developing trospium, is and KarXT we KarXT, the schizophrenia. registration. partner with study
be to medicine with to of new financial schizophrenia Yajing a commercial plans option. will potential products with very new a progress results. Yajing? FDA submit the could Karuna globally. And patients launch for treatment the of our XXXX, if third in It second the in a of has class drug important and about a KarXT in and quarter now, half application approved. speak China the XXXX
